Navigation Links
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Date:5/13/2009

OXFORD, England, May 13 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated a phase II clinical development programme for its ragweed allergy therapy. The treatment for allergic rhino-conjunctivitis caused by ragweed pollen is based on Circassia's ToleroMune(R) technology, which has previously achieved successful phase II results in patients with cat allergies. Ragweed is one of the leading causes of allergic reactions in North America, where allergies to its pollen are commonly referred to as 'hay fever'. Circassia is undertaking its latest phase II clinical study in Canada. The double-blind, randomised trial will include 50 patients with confirmed ragweed allergies, and will compare a range of ToleroMune doses with placebo. Unlike most current immunotherapies, which require careful dose escalation over many months and several years of maintenance doses, patients will receive just four standardized doses of ToleroMune treatment over a number of weeks. During the trial investigators will 'challenge' the volunteers with ragweed pollen to assess the impact of the therapy. "Broadening the range of allergies targeted by ToleroMune is an important step for Circassia, underlining our confidence in this breakthrough technology. We have already achieved encouraging results in patients with cat allergies, and are excited to be extending our portfolio of therapies to encompass ragweed allergy," said Steve Harris, Circassia's CEO. "Allergies to ragweed pollen are very common in the US, where they affect over a quarter of the population, and are a growing problem in Europe. We believe that Circassia's new therapy should offer patients important benefits, as ToleroMune has the potential to address the underlying cause of allergy using short, simple courses of treatment that minimize the risk of severe and sometimes life-threatening side effects associated with many existing treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments. Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts:
    Steve Harris
    Rob Budge
    CEO RJB Communications
    Circassia
    Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
2. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
3. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
4. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
9. AFFiRiS Begins Development of a Parkinsons Vaccine
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):